The HIV epidemic in Southern Africa - Is an AIDS-free generation possible?

Current HIV/AIDS Reports

Volumn 11, Issue 2, 2014, Pages 99-108

  Delva, Wim ^a,b,c   Abdool Karim, Quarraisha ^d  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b HASSELT UNIVERSITY   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

^d UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

AIDS; AIDS free generation; ART; Combination prevention; Global epidemic; HIV positive; Infection; Microbicides; Review; South Africa; Southern Africa

Indexed keywords

ANTIVIRUS AGENT; MICROBICIDE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGE DISTRIBUTION; BEHAVIORAL ECONOMICS; EPIDEMIC; HEALTH PROGRAM; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INCIDENCE; MORTALITY; REVIEW; SCALE UP; SEXUAL BEHAVIOR; SEXUAL TRANSMISSION; SWAZILAND; TRANSACTIONAL SEX; VIRUS LOAD; VULNERABLE POPULATION; ADOLESCENT; ADULT; AFRICA; AGED; DEVELOPING COUNTRY; EPIDEMICS; EPIDEMIOLOGY; FEMALE; HEALTH; HIV INFECTIONS; MALE; MIDDLE AGED; PREVALENCE; SENTINEL SURVEILLANCE; STATISTICS AND NUMERICAL DATA; TRENDS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AFRICA, SOUTHERN; AGED; AGED, 80 AND OVER; DEVELOPING COUNTRIES; EPIDEMICS; FEMALE; GLOBAL HEALTH; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PREVALENCE; SENTINEL SURVEILLANCE; YOUNG ADULT;

EID: 84903627609     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-014-0205-0     Document Type: Review

References (70)

1. UNAIDS. In: AIDSinfo. 2013. http://www.unaids.org/en/dataanalysis/ datatools/aidsinfo/. Last accessed on 30 Dec 2013.
2. Mayosi BM, Lawn JE, van Niekerk A, et al. Health in South Africa: changes and challenges since 2009. Lancet. 2012;380(9858):2029-43.
3. •• UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2013. 2013. Available at:http://www.unaids.org/en/media/unaids/ contentassets/documents/epidemiology/2013/gr2013/UNAIDS-Global-Report-2013-en. pdf. Last accessed on 30 Dec 2013. The UN Report is the most comprehensive source of up-to-date epidemiological information regarding the state of the epidemic.
4. •• Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493-505. Describes the results of the seminal study which demonstrated a significant reduction of HIV transmission in HIV+ patients on antiretroviral therapy.
5. Abdool Karim SS, Abdool Karim Q. Antiretroviral prophylaxis: a defining moment in HIV control. Lancet. 2011;378(9809):e23-5.
6. Fauci AS, Folkers GK, Dieffenbach CW. HIV-AIDS: much accomplished, much to do. Nat Immunol. 2013;14(11):1104-7.
7. Shisana O. HIV/AIDS in South Africa: at last the glass is half full. In: 6th South African AIDS Conference. Durban, South Africa. 2013. Available at http://www.hsrc.ac.za/en/media-briefs/hiv-aids-stis-and-tb/plenary-session-3-20- june-2013-hiv-aids-in-south-africa-at-last-the-glass-is-half-full-sthash. RebdY4w1.dpuf.
8. • Cremin I, Alsallaq R, Dybul M, Piot P, Garnett G, Hallett TB. The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis. AIDS. 2013;27(3):447-58. An important modelling analysis which highlights the potential impact of treatment as prevention on epidemiologic trajectories.
9. Abdool Karim SS, Churchyard GJ, Abdool Karim Q, Lawn SD. HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. Lancet. 2009;374(9693):921-33.
10. Novitsky V, Ndung'u T, Wang R, Bussmann H, Chonco F, Makhema J, et al. Extended high viremics: a substantial fraction of individuals maintain high plasma viral RNA levels after acute HIV-1 subtype C infection. AIDS. 2011;25(12):1515-22. doi:10.1097/QAD.0b013e3283471eb2.
11. Goodreau SM, Cassels S, Kasprzyk D, Montano DE, Greek A, Morris M. Concurrent partnerships, acute infection and HIV epidemic dynamics among young adults in Zimbabwe. AIDS Behav. 2012;16(2):312-22.
12. Robinson K, Cohen T, Colijn C. The dynamics of sexual contact networks: effects on disease spread and control. Theor Popul Biol. 2012;81(2):89-96.
13. Hool A, Leventhal GE, Bonhoeffer S. Virus-induced target cell activation reconciles set-point viral load heritability and within-host evolution. Epidemics. 2013;5(4):174-80.
14. Muller V, Fraser C, Herbeck JT. A strong case for viral genetic factors in HIV virulence. Viruses. 2011;3(3):204-16.
15. Murnane PM, Hughes JP, Celum C, Lingappa JR, Mugo N, Farquhar C, et al. Using plasma viral load to guide antiretroviral therapy initiation to prevent HIV-1 transmission. PLoS One. 2012;7(11):e51192.
16. Gouws E, Cuchi P, International Collaboration on Estimating HIV Incidence by Modes of Transmission. Focusing the HIV response through estimating the major modes of HIV transmission: a multi-country analysis. Sex Transm Infect. 2012;88 Suppl 2:i76-85.
17. Asher AK, Hahn JA, Couture MC, Maher K, Page K. People who inject drugs, HIV risk, and HIV testing uptake in sub-Saharan Africa. J Assoc Nurses AIDS Care. 2013;24(6):e35-44.
18. Pruss-Ustun A, Wolf J, Driscoll T, Degenhardt L, Neira M, Calleja JM. HIV due to female sex work: regional and global estimates. PLoS One. 2013;8(5):e63476.
19. Tanser F, de Oliveira T, Maheu-Giroux M, Barnighausen T. Concentrated HIV subepidemics in generalized epidemic settings. Curr Opin HIVAIDS. 2014;9(2):115-25.
20. Chersich MF, Luchters S, Ntaganira I, Gerbase A, Lo YR, Scorgie F, et al. Priority interventions to reduce HIV transmission in sex work settings in sub-Saharan Africa and delivery of these services. J Int AIDS Soc. 2013;16(1):17980.
21. Makofane K, Gueboguo C, Lyons D, Sandfort T. Men who have sex with men inadequately addressed in African AIDS National Strategic Plans. Glob Public Health. 2013;8(2):129-43.21.
22. Ngugi EN, Roth E, Mastin T, Nderitu MG, Yasmin S. Female sex workers in Africa: epidemiology overview, data gaps, ways forward. SAHARA J. 2012;9(3):148-53.
23. Bicego GT, Nkambule R, Peterson I, Reed J, Donnell D, Ginindza H, et al. Recent patterns in population-based HIV prevalence in Swaziland. PLoS One. 2013;8(10):e77101.
24. van Loggerenberg F, Dieter AA, Sobieszczyk ME, Werner L, Grobler A, Mlisana K, et al. HIV prevention in high-risk women in South Africa: condom use and the need for change. PLoS One. 2012;7(2):e30669.
25. Conn C. Young African women must have empowering and receptive social environments for HIV prevention. AIDS Care. 2013;25(3):273-80.
26. Andersson N, Cockcroft A. Choice-disability and HIV infection: a cross sectional study of HIV status in Botswana, Namibia and Swaziland. AIDS Behav. 2012;16(1):189-98.
27. Yi TJ, Shannon B, Prodger J, McKinnon L, Kaul R. Genital immunology and HIV susceptibility in young women. Am J Reprod Immunol. 2013;69 Suppl 1:74-9.
28. d'Albis H, Augeraud-Veron E, Djemai E, Ducrot A. The dispersion of age differences between partners and the asymptotic dynamics of the HIV epidemic. J Biol Dyn. 2012;6(2):695-717.
29. Bershteyn A, Klein DJ, Eckhoff PA. Age-dependent partnering and the HIV transmission chain: a microsimulation analysis. J R Soc Interface. 2013;10(88):20130613.
30. Beauclair R, Kassanjee R, Temmerman M, Welte A, Delva W. Age-disparate relationships and implications for STI transmission among young adults in Cape Town, South Africa. Eur J Contracept Reprod Health Care. 2012;17(1):30-9.
31. Zembe YZ, Townsend L, Thorson A, Ekstrom AM. "Money talks, bullshitwalks" interrogating notions of consumption and survival sex among young women engaging in transactional sex in post-apartheid South Africa: a qualitative enquiry. Glob Health. 2013;9:28.
32. Beauclair R, Delva W. Is younger really safer? A qualitative study of perceived risks and benefits of age-disparate relationships among women in Cape Town, South Africa. PLoS One 2013;8(11):e81748.
33. Cluver L, Boyes M, Orkin M, Pantelic M, Molwena T, Sherr L. Child-focused state cash transfers and adolescent risk of HIVinfection in South Africa: a propensity-score-matched case -control study. Lancet Glob Health. 2013;1(6):e362-70.
34. Baird SJ, Garfein RS, McIntosh CT, Ozler B. Effect of a cash transfer programme for schooling on prevalence of HIVand herpes simplex type 2 in Malawi: a cluster randomised trial. Lancet. 2012;379(9823):1320-9.
35. •• Abdool Karim Q, Kharsany ABM, Frohlich JA, Werner L, Mlotshwa M, Madlala BT, et al. HIV Incidence in Young Girls in KwaZulu-Natal, South Africa-Public Health Imperative for Their inclusion in HIV Biomedical Intervention Trials. AIDS Behav. 2012;16(7):1870-6. PMC3460144 This survey highlights the magnitude of the burden of HIV in adolescent girls.
36. Kharsany AB, Mlotshwa M, Frohlich JA, Yende Zuma N, Samsunder N, Abdool Karim SS, et al. HIV prevalence among high school learners - opportunities for schools-based HIV testing programmes and sexual reproductive health services. BMC Public Health. 2012;12:231. PMC3359203.
37. April MD, Wood R, Berkowitz BK, Paltiel AD, Anglaret X, Losina E, et al. The Survival Benefits of Antiretroviral Therapy in South Africa. J Infect Dis. 2014;209(4):491-9.
38. Eaton JW, Johnson LF, Salomon JA, Barnighausen T, Bendavid E, Bershteyn A, et al. HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med. 2012;9(7):e1001245.
39. Bor J, Herbst AJ, Newell ML, Barnighausen T. Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science. 2013;339(6122):961-5.
40. • Tanser F, Barnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIVacquisition in rural KwaZulu-Natal, South Africa. Science. 2013;339(6122): 966-71. This study highlights the potential population-level impact of ART scale-up.
41. Zaidi J, Grapsa E, Tanser F, Newell ML, Barnighausen T. Dramatic increase in HIVprevalence after scale-up of antiretroviral treatment. AIDS. 2013;27(14):2301-5.
42. Johnson LF, Mossong J, Dorrington RE, Schomaker M, Hoffmann CJ, Keiser O, et al. Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med. 2013;10(4):e1001418.
43. • Walensky RP, Ross EL, Kumarasamy N, Wood R, Noubary F, Paltiel AD, et al. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med. 2013;369(18):1715-25. This study highlights the economic arguments for immediate initiation of ART in HIV+ patients.
44. Hontelez JA, Lurie MN, Barnighausen T, Bakker R, Baltussen R, Tanser F, et al. Elimination of HIVin South Africa through expanded access to antiretroviral therapy: amodel comparison study. PLoS Med. 2013;10(10):e1001534.
45. Barnighausen T, Bloom DE, Humair S. Economics of antiretroviral treatment vs. circumcision for HIV prevention. Proc Natl Acad Sci U S A. 2012;109(52):21271-6.
46. Granich R, Kahn JG, Bennett R, Holmes CB, Garg N, Serenata C, et al. Expanding ART for treatment and prevention of HIVin South Africa: estimated cost and cost-effectiveness 2011-2050. PLoS One. 2012;7(2):e30216.
47. Cohen MS, Smith MK, Muessig KE, Hallett TB, Powers KA, Kashuba AD. Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where dowe go fromhere? Lancet. 2013;382(9903): 1515-24.
48. Delva W, Fleming Y, Chingandu L. When to start ART in Africa-primarily guided by RCTs or patient autonomy? J Int AIDS Soc. 2013;16:18756.
49. Nosyk B, Audoin B, Beyrer C, Cahn P, Granich R, Havlir D, et al. Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria. AIDS. 2013;27(7):1159-65.
50. Gabillard D, Lewden C, Ndoye I, Moh R, Segeral O, Tonwe-Gold B, et al. Mortality, AIDS-morbidity, and loss to follow-up by current CD4 cell count among HIV-1-infected adults receiving antiretroviral therapy in Africa and Asia: data from the ANRS 12222 collaboration. J Acquir Immune Defic Syndr. 2013;62(5):555-61.
51. Le T, Wright EJ, Smith DM, He W, Catano G, Okulicz JF, et al. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med. 2013;368(3):218-30.
52. Hirnschall G, Harries AD, Easterbrook PJ, Doherty MC, Ball A. The next generation of the World Health Organization's global antiretroviral guidance. J Int AIDS Soc. 2013;16:18757.
53. Sibbald B. HIV prevention: new pilots for beleaguered Swaziland. Lancet. 2013;381(9861):103-4.
54. Novitsky V, Wang R, Bussmann H, Lockman S, Baum M, Shapiro R, et al. HIV-1 subtype C-infected individuals maintaining high viral load as potential targets for the " test-andtreat" approach to reduce HIV transmission. PLoS One. 2010;5(4):e10148.
55. Hayes R, Ayles H, Beyers N, Sabapathy K, Floyd S, Shanaube K, et al. HPTN 071 (PopART) Study Team. HPTN 071 (PopART): Rationale and design of a cluster-randomised trial of the population impact of an HIV combination prevention intervention including universal testing and treatment - a study protocol for a cluster randomised trial. Trials. 2014;15(1):57.
56. Iwuji CC, Orne-Gliemann J, Tanser F, Boyer S, Lessells RJ, Lert F, et al. Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a cluster randomised controlled trial. Trials 2013;14:230.
57. Chen Y. Treatment-related optimistic beliefs and risk of HIV transmission: a review of recent findings (2009-2012) in an era of treatment as prevention. Curr HIV/AIDS Rep. 2013;10(1):79-88.
58. McGrath N, Eaton JW, Barnighausen TW, Tanser F, Newell ML. Sexual behaviour in a rural high HIV prevalence South African community: time trends in the antiretroviral treatment era. AIDS. 2013;27(15):2461-70.
59. Stover J, Brown T, Marston M. Updates to the Spectrum/Estimation and Projection Package (EPP) model to estimate HIV trends for adults and children. Sex Transm Infect. 2012;88 Suppl 2:i11-6.
60. Halperin DT, Mugurungi O, Hallett TB, Muchini B, Campbell B, Magure T, et al. A surprising prevention success: why did the HIV epidemic decline in Zimbabwe? PLoS Med. 2011;8(2):e1000414.
61. Johnson LF, Hallett TB, Rehle TM, Dorrington RE. The effect of changes in condom usage and antiretroviral treatment coverage on human immunodeficiency virus incidence in South Africa: a model-based analysis. J R Soc Interface. 2012;9(72):1544-54.
62. Langhaug L, Buzdugan R, Copas A, Dirawo J, Benedict C, Mundida O, et al. Change over time (2007-2009) in HIV preventive behaviours, evidence fromtwo serial population-based surveys in rural Zimbabwe. Trop Med Int Health. 2012;17(7):827-35.
63. Shisana O, Rehle T, Simbayi L, Zuma K, Jooste S, Pillay-van-Wyk V, et al. South African national HIV prevalence, incidence, behaviour and communication survey 2008: A turning tide among teenagers? Cape Town: Human Sciences Research Council; 2009.
64. Cori A, Ayles H, Beyers N, Schaap A, Floyd S, Sabapathy K, et al. HPTN 071 (PopART) study team. HPTN 071 (PopART): A Cluster-Randomized Trial of the Population Impact of an HIV Combination Prevention Intervention Including Universal Testing and Treatment: Mathematical Model. PLoS One. 2014;9(1):e84511.
65. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Baxter C, Mansoor L, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168-74.
66. Karim SS, Karim Q. Effectiveness and safety of vaginal microbicide 1% tenofovir gel for prevention of HIV infection in women. Abstract TUSS0204 presented at the XVIII International AIDS Conference; July 18-23, 2010; Vienna, Austria
67. Mossong J, Grapsa E, Tanser F, Barnighausen T, Newell ML. Modelling HIV incidence and survival from age-specific seroprevalence after antiretroviral treatment scale-up in rural South Africa. AIDS. 2013;27(15):2471-9.
68. Mahiane GS, Ouifki R, Brand H, Delva W, Welte A. A general HIV incidence inference scheme based on likelihood of individual level data and a population renewal equation. PLoS One. 2012;7(9):e44377.
69. • Kassanjee R, McWalter TA, Barnighausen T, Welte A. A new general biomarker-based incidence estimator. Epidemiology. 2012;23(5):721 - 8. Describes exciting new biomarker-based approach for evaluating HIV incidence which is needed to accurately monitor epidemiological trends of HIV.
70. Laeyendecker O, Kulich M, Donnell D, Komarek A, Omelka M, Mullis CE, et al. Development of methods for cross-sectional HIV incidence estimation in a large, community randomized trial. PLoS One. 2013;8(11):e78818.